natgillin/translations-raw huggingface dataset:
Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased.
Tumorji lahko pospešijo normalno spreminjanje kosti tako, da se poveča sproščanje kalcija iz kosti.
- A kidney function disorder called Fanconi syndrome (will normally be determined by your doctor with certain urine tests).
- Okvara v delovanju ledvic, imenovana Fanconijev sindrom (običajno jo ugotovi zdravnik s pomočjo določenih preiskav urina).
From a microbiological point of view, the solution for infusion should be used immediately after dilution.
Z mikrobiološkega stališča je treba raztopino za infundiranje uporabiti takoj po redčenju.
Zoledronic acid Actavis is not recommended for use in adolescents and children below the age of 18 years.
Zdravila Zoledronska kislina Actavis ni priporočljivo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
abdominal pain, dry mouth.
stomatitis, suha usta.
The SRE rate (events/person year) was 0.628 for zoledronic acid and 1.096 for placebo.
Pogostnost SRE (dogodki/človek-leto) je bila 0,628 z zoledronsko kislino in 1,096 s placebom.
Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve.
Podaljšanje časa infundiranja s 5 na 15 minut je povzročilo 30% znižanje koncentracije zoledronske kisline ob koncu infuzije, ni pa vplivalo na površino pod krivuljo plazemske koncentracije po času.
The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks.
Obdobje zdravljenja v študiji je trajalo 12 mesecev; pred tem so bolniki opravili od 4- do 9-tedensko obdobje presejanja, med katerim so vsaj 2 tedna jemali vitamin D in dodatke elementarnega kalcija.
As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population.
Za bolnike s hudo insuficienco jeter je kliničnih podatkov malo, zato za to populacijo bolnikov ni mogoče dati specifičnih priporočil.
- if you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with Zoledronic acid Actavis and inform your doctor about your dental treatment.
- če imate kakšno zobozdravstveno zdravljenje ali imate predviden kakšen zobozdravstveni poseg, morate svojemu zobozdravniku povedati, da dobivate zdravilo Zoledronska kislina Actavis in obvestite svojega zdravnika o zdravljenju zob.
Your doctor, pharmacist or nurse knows how to store Zoledronic acid Actavis properly.
Vaš zdravnik, farmacevt ali medicinska sestra vedo, kako pravilno shranjevati zdravilo Zoledronska kislina Actavis.
- Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.
- Huda alergijska reakcija: kratka sapa, oteklost predvsem obraza in žrela.
Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.
V opravljenih testih mutagenosti zoledronska kislina ni bila mutagena, testiranje kancerogenosti pa ni dalo nobenih dokazov o kancerogenem potencialu.
Limited pharmacokinetic data in children with severe osteogenesis imperfecta suggest that zoledronic acid pharmacokinetics in children aged 3 to 17 years are similar to those in adults at a similar mg/kg dose level.
Omejeni farmakokinetični podatki pri otrocih s hudo osteogenesis imperfecta kažejo, da so farmakokinetične lastnosti zoledronske kisline pri otrocih v starosti od 3 do 17 let pri podobni ravni odmerjanja v mg/kg podobne kot pri odraslih.
- Blurred vision, tearing of the eye, eye sensitivity to light.
- Zamegljen vid, solzenje, občutljivost oči za svetlobo.
- Low counts of white blood cells and blood platelets.
- Majhno število belih krvnih celic in krvnih ploščic.
If your level of calcium falls too low, you may have to be given supplemental calcium by infusion.
Če se vam koncentracija kalcija preveč zniža, boste morda morali dobiti dodatni kalcij z infuzijo.
Untreated hypercalcaemia patients generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.
Bolniki z nezdravljeno hiperkalciemijo imajo na splošno določeno mero okvare ledvic, zato jim je treba natančno kontrolirati delovanje ledvic.
- For single use only.
- Samo za enkratno uporabo.
The highest non-lethal single intravenous dose was 10 mg/kg bodyweight in mice and 0.6 mg/kg in rats.
Največji neletalni enkratni intravenski odmerek je bil 10 mg/kg telesne mase pri miših in 0,6 mg/kg pri podganah.
Proportion of patients with SREs p-value
Delež bolnikov s SRE (%) Vrednost p
- Painful redness and/or swelling of the eye.
- Boleča pordelost in/ali oteklost oči.
In addition to being a potent inhibitor of bone resorption, zoledronic acid also possesses several anti-tumour properties that could contribute to its overall efficacy in the treatment of metastatic bone disease.
Poleg tega, da močno zavira resorpcijo kosti, ima zoledronska kislina tudi več protitumorskih lastnosti; te bi lahko pripomogle k njeni celotni učinkovitosti pri zdravljenju metastatske bolezni kosti.
Women of childbearing potential should be advised to avoid becoming pregnant.
Ženskam v rodni dobi je treba naročiti, naj pazijo, da ne bodo zanosile.
Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.
Bolnikom, ki nimajo previsoke koncentracije kalcija v krvi, bo zdravnik predpisal tudi dodatke kalcija in vitamina D, ki jih je treba jemati vsak dan.
Attention should also be paid to the possibility of hypomagnesaemia developing during treatment.
Pozornost je treba nameniti možnemu pojavu hipomagneziemije med zdravljenjem.
- Sudden coldness with fainting, limpness or collapse.
- Nenadna hladnost z omedlevico, šibkostjo ali kolapsom.
Very rare (may affect up to 1 in 10,000 people): - Fainting due to low blood pressure.
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): - Omedlevica zaradi nizkega krvnega tlaka.
MM/YYYY
MM. LLLL
Patients receiving zoledronic acid 4 mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24.
Prejemniki 4 mg zoledronske kisline so navajali manjši porast bolečin kot prejemniki placeba in razlika je bila značilna 3., 9., 21. in 24. mesec.
The following information is intended for healthcare professionals only: How to prepare and administer Zoledronic acid Actavis
Naslednje informacije so namenjene samo zdravstvenemu osebju: Priprava in dajanje zdravila Zoledronska kislina Actavis
Follow carefully all instructions given to you by your doctor.
Natančno upoštevajte vsa zdravnikova navodila.
Contains mannitol, sodium citrate and water for injections.
Vsebuje manitol, natrijev citrat in vodo za injekcije.
- Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
- antiangiogena zdravila (uporabljana za zdravljenjue raka), ker kombinacijo le-teh z zoledronsko kislino povezujejo s povečanim tveganjem za osteonekrozo čeljustnic (ONČ).
- if you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which Zoledronic acid Actavis belongs), or any of the other ingredients of this medicine (listed in section 6).
- če ste alergični na zoledronsko kislino, kakšen drug difosfonat (skupina zdravil, v katero spada zdravilo Zoledronska kislina Actavis) ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Acute renal failure, haematuria, proteinuria Acquired Fanconi syndrome
Akutna odpoved ledvic, hematurija, proteinurija Pridobljen Fanconijev sindrom
If a lower dose of Zoledronic acid Actavis is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution.
Če je potreben nižji odmerek zdravila Zoledronska kislina Actavis, najprej izvlecite ustrezno količino, kot je označeno spodaj, in nato naprej redčite s 100 ml raztopine za infundiranje.
Tell your doctor about any of the following serious side effects straight away:
Zdravniku morate takoj povedati, če se vam pojavi kateri od naslednjih resnih neželenih učinkov:
- Difficulty in breathing with wheezing or coughing.
- Težko dihanje s piskanjem ali kašljem.
These could be signs of bone damage in the jaw (osteonecrosis).
To so lahko znaki okvare čeljusti (osteonekroze).
Anxiety, sleep disturbance
Anksioznost, motnja spanja
Animal reproduction studies with zoledronic acid have shown reproductive toxicity (see section 5.3).
Reprodukcijske študije z zoledronsko kislino na živalih so pokazale reproduktivno toksičnost (glejte poglavje 5.3).
The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Naslednji neželeni učinki, navedeni v Preglednici 1, so zbrani iz kliničnih študij in iz postmarketinških poročil po pretežno kroničnemu zdravljenju s 4 mg zoledronske kisline:
There have been very rare cases of drowsiness and sleepiness with the use of zoledronic acid.
V zelo redkih primerih sta se med uporabo zoledronske kisline pojavili dremavost in zaspanost.
Estimated treatment effects on BMD were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid.
Ocenjeni učinki zdravljenja na MGK so bili podobni pri obeh učinkovinah, vendar načrt preskušanja ni bil dovolj robusten, da bi lahko potrdili neinferiornost zoledronske kisline.
5 ml concentrate in a plastic vial made of clear, colourless oleofinic polymer closed with fluoropolymer-coated bromobutyl rubber stopper and aluminium cap with plastic flip-off component.
5 ml koncentrata v plastični viali iz prozornega, brezbarvnega oleofinskega polimera, zaprti z zamaškom iz brombutilne gume, prekrite s fluoropolimerom, in aluminijsko zaporsko s plastičnim snemnim delom.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing zoledronic acid in all subsets of the paediatric population in the treatment of tumour-induced hypercalcaemia and prevention of skeletal-related events in patients with advanced malignancies involving bone (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z referenčnim zdravilom, ki vsebuje zoledronsko kislino za vse skupine pediatrične populacije glede zdravljenja tumorsko povzročene hiperkalciemije in preprečevanja z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
- Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys.
- Talidomid (zdravilo za zdravljenje določene vrste krvnega raka, ki zajame kosti) ali druga zdravila, ki lahko škodujejo ledvicam.
1.0 mg/dl or 88 micromol/l.
zvišanje za 1,0 mg/dl ali 88 mikromolov/l.
Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½ α 0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours.
Intravensko uporabljena zoledronska kislina se odstranjuje iz telesa v treh fazah: najprej se pojavi hitro dvofazno izginotje iz sistemskega obtoka z razpolovnima časoma t½ α 0,24 ure in t½β 1,87 ure, ki mu sledi dolga eliminacijska faza s terminalnim eliminacijskim razpolovnim časom t½γ 146 ur.
If refrigerated, the solution must be allowed to reach room temperature before administration.
Če je raztopina shranjena v hladilniku, je treba pustiti, da pred infundiranjem doseže sobno temperaturo.
Intravenous use after dilution.
Intravenska uporaba po razredčenju.
Zoledronic acid shows no appreciable binding to plasma proteins and does not inhibit human P450 enzymes in vitro (see section 5.2), but no formal clinical interaction studies have been performed.
Zoledronska kislina ne kaže znatne vezave na plazemske beljakovine in in vitro ne zavira človeških encimov P450 (glejte poglavje 5.2), a formalnih kliničnih študij medsebojnega delovanja niso izvedli.
Zoledronic acid Actavis is supplied as a clear and colourless concentrate for solution for infusion (sterile concentrate) in a plastic vial.
Zdravilo Zoledronska kislina Actavis je na voljo kot bister in brezbarven koncentrat za raztopino za infundiranje (sterilen koncentrat) v plastični viali.
- Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.
- Zdravnik vam bo priporočil, da pred vsakim zdravljenjem s tem zdravilom popijete dovolj vode;
It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.
Trenutno ni jasno, ali zoledronska kislina povzroča to neredno bitje srca, a če se vam potem, ko ste dobili zoledronsko kislino, pojavijo takšni simptomi, morate to povedati svojemu zdravniku.
The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.
Pričakovati je mogoče, da ti manjši odmerki pri bolnikih z okvaro ledvic dosežejo enake AUC, kot so pri bolnikih z očistkom kreatinina 75 ml/min.
- if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth.
- če imate ali ste imeli bolečine, oteklost ali omrtvičenost čeljusti, občutek teže v čeljusti ali majanje zoba.
- If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Zoledronic acid Actavis.
- Če zdravilo dobivate za zmanjšanje količine kalcija v krvi, boste praviloma dobili le eno infuzijo zdravila Zoledronska kislina Actavis.
Zoledronic acid Actavis is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Zdravilo Zoledronska kislina Actavis ni priporočljivo za bolnike, ki imajo že pred uvedbo zdravljenja hudo okvaro ledvic, ki je za to populacijo bolnikov opredeljena kot CLcr < 30 ml/min.
In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4).
V kliničnih študijah so zdravljenje z zoledronsko kislino nadaljevali šele, ko se je koncentracija kreatinina vrnila na raven znotraj 10% od izhodiščne vrednosti (glejte poglavje 4.4).
The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06-0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose.
V dolgoročnih živalskih študijah ponavljajočih se parenteralnih odmerkov so bile varnostne meje glede na ledvične učinke ozke, toda kumulativna raven brez neželenih učinkov (NOAEL) v študijah enkratnega odmerka (1,6 mg/kg) in večkratnih odmerkov do en mesec (0,06 do 0,6 mg/kg/dan) niso pokazale ledvičnih učinkov v odmerkih, ki so bili enakovredni največjemu terapevtskemu odmerku za človeka ali večji od njega.
Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.
Bolniki morajo dobivati tudi peroralni dodatek 500 mg kalcija in 400 IE vitamina D na dan.
From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney.
Iz kostnega tkiva se zelo počasi sprošča nazaj v sistemski obtok in se iz telesa izloča skozi ledvice.
• To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).
• Za preprečevanje zapletov na kosteh, npr. zlomov, pri odraslih bolnikih z metastazami v kosteh (z razširitvijo raka s prvotnega mesta na kosti).
The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3-4 weeks in oncology patients.
Neravnovesja, opaženega v tem preskušanju, niso opažali v drugih preskušanjih z zoledronsko kislino, vključno s preskušanji 4 mg zoledronske kisline vsake 3-4 tedne pri onkoloških bolnikih.
While being treated with Zoledronic acid Actavis, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
V času zdravljenja z zdravilom Zoledronska kislina Actavis morate skrbeti za dobro ustno higieno (kar vključuje redno čiščenje zob) in redno hoditi na rutinske preglede k zobozdravniku.
Table 3: Efficacy results (solid tumours other than breast or prostate cancer)
Preglednica 3: Rezultati učinkovitosti (drugi parenhimski tumorji razen raka dojke ali prostate)
Clinical trial results in the treatment of TIH
Rezultati kliničnih preskušanj v zdravljenju TIH
In paediatric patients with severe osteogenesis imperfecta, zoledronic acid seems to be associated with more pronounced risks for acute phase reaction, hypocalcaemia and unexplained tachycardia, in comparison to pamidronate, but this difference declined after subsequent infusions.
Pri pediatričnih bolnikih s hudo osteogenesis imperfecta je zoledronska kislina povezana z večjim tveganjem za reakcijo akutne faze, hipokalciemijo in nepojasnjeno tahikardijo kot uporaba pamidronata, vendar se je z nadaljnjimi infuzijami ta razlika zmanjševala.
This condition is known as tumour-induced hypercalcaemia (TIH).
To motnjo imenujemo tumorsko povzročena hiperkalciemija (TIH).
Table 2: Efficacy results (prostate cancer patients receiving hormonal therapy)
Preglednica 2: Rezultati učinkovitosti (bolniki z rakom prostate, ki prejemajo hormonsko zdravljenje)
- Carefully follow all the other instructions given to you by your doctor, pharmacist or nurse.
- Natančno upoštevajte tudi vsa druga navodila, ki jih dobite od svojega zdravnika, farmacevta ali medicinske sestre.
Table 6: Adverse reactions observed in paediatric patients with severe osteogenesis imperfecta1 Nervous system disorders
Preglednica 6: Neželeni učinki, ugotovljeni pri pediatričnih bolnikih s hudo osteogenesis imperfecta1 Bolezni živčevja
In clinical studies, zoledronic acid, used as indicated in sections 4.1 and 4.2, has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring.
V kliničnih študijah so zoledronsko kislino, uporabljeno, kot je navedeno v poglavjih 4.1 in 4.2, dajali sočasno s pogosto uporabljanimi zdravili proti raku, diuretiki, antibiotiki in analgetiki, ne da bi prišlo do klinično očitnega medsebojnega delovanja.
Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change.
Zoledronska kislina deluje tako, da se veže na kost in upočasni hitrost spreminjanja kosti.
Clinical experience with acute overdose of zoledronic acid is limited.
Kliničnih izkušenj z akutnim prevelikim odmerjanjem zoledronske kisline je malo.
What Zoledronic acid Actavis is and what it is used for What you need to know before you are given Zoledronic acid Actavis How Zoledronic acid Actavis is used Possible side effects
Kaj je zdravilo Zoledronska kislina Actavis in za kaj ga uporabljamo Kaj morate vedeti, preden boste dobili zdravilo Zoledronska kislina Actavis Kako se uporablja zdravilo Zoledronska kislina Actavis Možni neželeni učinki
One vial contains 5 ml of solution.
Ena viala vsebuje 5 ml raztopine.
Caution is indicated when Zoledronic acid Actavis is used with other potentially nephrotoxic medicinal products.
Previdnost je potrebna, če je zdravilo Zoledronska kislina Actavis uporabljeno skupaj z drugimi potencialno nefrotoksičnimi zdravili.
Thrombocytopenia, leukopenia
Trombocitopenija, levkopenija
Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance < 30 ml/min).
Farmakokinetičnih podatkov o bolnikih s hudo insuficienco ledvic (očistek kreatinina < 30 ml/min) je malo.
Median time to SRE (days)
Mediani čas do SRE
The dose must be given as a single intravenous infusion over no less than 15 minutes.
Odmerek je treba dati v enkratni intravenski infuziji v času, ki ne sme biti krajši od 15 minut.
The active substance in Zoledronic acid Actavis is zoledronic acid, which belongs to a group of substances called bisphosphonates.
Zdravilna učinkovina v zdravilu Zoledronska kislina Actavis je zoledronska kislina, ki spada v skupino snovi, imenovanih difosfonati.
- Do not use Zoledronic acid Actavis after the expiry date stated on the vial and carton after EXP. - This medicinal product does not require any specific storage conditions.
- Zdravila Zoledronska kislina Actavis ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali in škatli poleg oznake EXP. - To zdravilo ne potrebuje posebnih pogojev za shranjevanje.
Prevention of skeletal related events in patients with advanced malignancies involving bone Adults and older people
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti Odrasli in starejši bolniki
In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid Actavis is used in combination with thalidomide.
Pri bolnikih z multiplim mielomom se utegne lahko tveganje za moteno delovanje ledvic poveča, če je zdravilo Zoledronska kislina Actavis uporabljeno v kombinaciji s talidomidom.
In the event of hypocalcaemia, calcium gluconate infusions should be administered as clinically indicated.
V primeru hipokalciemije je treba dati infuzijo kalcijevega glukonata, če je to klinično indicirano.
Angioneurotic oedema
Angionevrotični edem
In the clinical programme patients aged 1 to < 3 years received 0.025 mg/kg zoledronic acid (up to a maximum single dose of 0.35 mg) every 3 months and patients aged 3 to 17 years received 0.05 mg/kg zoledronic acid (up to a maximum single dose of 0.83 mg) every 3 months.
V kliničnem programu so bolniki v starosti od 1 do < 3 leta prejemali 0,025 mg/kg zoledronske kisline (do največ 0,35 mg v enkratnem odmerku) na 3 mesece, bolniki v starosti od 3 do 17 let pa 0,05 mg/kg zoledronske kisline (do največ 0,83 mg v enkratnem odmerku) na 3 mesece.
1Adverse events occurring with frequencies < 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid as indicated in sections 4.1 and 4.2 (see section 4.8)
Hipofosfatemija 1Neželene učinke s pogostnostjo < 5% so ocenili z medicinskega vidika in pokazalo se je, da se ujemajo z že ugotovljenimi varnostnimi značilnostmi zoledronske kisline, uporabljene, kot je navedeno v poglavjih 4.1 in 4.2 (glejte poglavje 4.8).
Aseptic techniques must be followed during the preparation of the infusion.
Pri pripravi infuzije je treba upoštevati aseptične postopke.
Thus these results precluded determining a definitive effect of zoledronic acid on fertility in humans.
Na podlagi teh rezultatov ni mogoče določiti dejanskega vpliva zoledronske kisline na plodnost pri človeku.
While the risk is reduced with a dose of 4 mg zoledronic acid administered over 15 minutes, deterioration in renal function may still occur.
Čeprav se tveganje zmanjša, če traja dajanje 4 mg odmerka zoledronske kisline 15 minut, se delovanje ledvic kljub temu lahko poslabša.
There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid.
Korigirani serumski kalcij se je hitreje normaliziral 4. dan z 8 mg zoledronske kisline in 7. dan s 4 mg in 8 mg zoledronske kisline.